FY2022 EPS Estimates for Aurinia Pharmaceuticals Inc. Boosted by Analyst (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) – Equities researchers at Cantor Fitzgerald increased their FY2022 earnings per share (EPS) estimates for Aurinia Pharmaceuticals in a research report issued on Wednesday, May 11th. Cantor Fitzgerald analyst O. Brayer now expects that the biotechnology company will post earnings per share of ($0.59) for the year, up from their prior forecast of ($0.67). Cantor Fitzgerald has a “Overweight” rating on the stock.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last issued its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). Aurinia Pharmaceuticals had a negative net margin of 253.66% and a negative return on equity of 45.48%. During the same quarter last year, the business earned ($0.40) EPS.

A number of other research analysts also recently issued reports on AUPH. SVB Leerink decreased their target price on shares of Aurinia Pharmaceuticals from $30.00 to $22.00 and set an “outperform” rating for the company in a research report on Tuesday, March 8th. HC Wainwright reduced their price target on shares of Aurinia Pharmaceuticals from $33.00 to $30.00 in a research report on Wednesday, May 4th. StockNews.com started coverage on shares of Aurinia Pharmaceuticals in a research note on Thursday, March 31st. They set a “sell” rating for the company. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Finally, Royal Bank of Canada dropped their price target on shares of Aurinia Pharmaceuticals from $27.00 to $22.00 and set an “outperform” rating for the company in a research note on Thursday, April 28th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals has an average rating of “Hold” and a consensus price target of $25.60.

Shares of AUPH opened at $9.89 on Friday. The firm has a market capitalization of $1.40 billion, a PE ratio of -7.73 and a beta of 1.09. Aurinia Pharmaceuticals has a 1-year low of $8.86 and a 1-year high of $33.97. The company’s fifty day moving average price is $11.39 and its 200-day moving average price is $17.62.

A number of institutional investors and hedge funds have recently made changes to their positions in AUPH. Rockefeller Capital Management L.P. grew its stake in Aurinia Pharmaceuticals by 0.5% during the third quarter. Rockefeller Capital Management L.P. now owns 93,585 shares of the biotechnology company’s stock worth $2,071,000 after buying an additional 500 shares during the period. Diamond Hill Capital Management Inc. raised its holdings in Aurinia Pharmaceuticals by 3.9% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 19,184 shares of the biotechnology company’s stock valued at $439,000 after acquiring an additional 715 shares in the last quarter. Deutsche Bank AG raised its holdings in Aurinia Pharmaceuticals by 10.4% in the fourth quarter. Deutsche Bank AG now owns 8,185 shares of the biotechnology company’s stock valued at $187,000 after acquiring an additional 768 shares in the last quarter. Swiss National Bank raised its holdings in shares of Aurinia Pharmaceuticals by 0.4% during the third quarter. Swiss National Bank now owns 226,500 shares of the biotechnology company’s stock worth $5,012,000 after purchasing an additional 1,000 shares during the period. Finally, Macquarie Group Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth $26,000. Institutional investors own 33.09% of the company’s stock.

About Aurinia Pharmaceuticals (Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Further Reading